B. Riley reaffirmed their buy rating on shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in a research report released on Monday morning. B. Riley currently has a $50.00 price objective on the specialty pharmaceutical company’s stock.

Several other research firms have also recently weighed in on SUPN. Stifel Nicolaus cut Supernus Pharmaceuticals from a buy rating to a hold rating and set a $47.00 price objective for the company. in a report on Tuesday, September 19th. They noted that the move was a valuation call. Piper Jaffray Companies reiterated a hold rating and issued a $41.00 price objective on shares of Supernus Pharmaceuticals in a report on Tuesday, September 26th. FBR & Co initiated coverage on Supernus Pharmaceuticals in a report on Thursday, October 19th. They issued a buy rating and a $53.00 price objective for the company. Zacks Investment Research upgraded Supernus Pharmaceuticals from a hold rating to a strong-buy rating and set a $47.00 price objective for the company in a report on Wednesday, November 8th. Finally, BidaskClub upgraded Supernus Pharmaceuticals from a hold rating to a buy rating in a report on Thursday, August 17th. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $49.60.

Shares of Supernus Pharmaceuticals (SUPN) opened at $38.10 on Monday. Supernus Pharmaceuticals has a fifty-two week low of $20.55 and a fifty-two week high of $50.04. The firm has a market capitalization of $1,950.00, a P/E ratio of 35.85, a price-to-earnings-growth ratio of 1.61 and a beta of 1.30.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The business had revenue of $80.40 million during the quarter, compared to analysts’ expectations of $78.74 million. The business’s revenue for the quarter was up 41.5% on a year-over-year basis. analysts expect that Supernus Pharmaceuticals will post 1.07 earnings per share for the current year.

WARNING: “Supernus Pharmaceuticals’ (SUPN) Buy Rating Reaffirmed at B. Riley” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.watchlistnews.com/supernus-pharmaceuticals-supn-buy-rating-reaffirmed-at-b-riley/1717593.html.

In other news, SVP Padmanabh P. Bhatt sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, September 8th. The stock was sold at an average price of $49.86, for a total value of $249,300.00. Following the completion of the transaction, the senior vice president now owns 12,500 shares in the company, valued at approximately $623,250. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Stefan K.F. Schwabe sold 95,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $46.59, for a total value of $4,426,050.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 150,000 shares of company stock valued at $7,055,350. 6.70% of the stock is currently owned by company insiders.

A number of hedge funds have recently bought and sold shares of SUPN. Vanguard Group Inc. increased its position in Supernus Pharmaceuticals by 39.1% during the 2nd quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock valued at $150,873,000 after buying an additional 984,200 shares in the last quarter. Emerald Advisers Inc. PA bought a new position in Supernus Pharmaceuticals during the 2nd quarter valued at approximately $21,474,000. Emerald Mutual Fund Advisers Trust bought a new position in Supernus Pharmaceuticals during the 2nd quarter valued at approximately $17,553,000. Pictet Asset Management Ltd. increased its position in Supernus Pharmaceuticals by 438.7% during the 3rd quarter. Pictet Asset Management Ltd. now owns 491,283 shares of the specialty pharmaceutical company’s stock valued at $19,651,000 after buying an additional 400,083 shares in the last quarter. Finally, Hodges Capital Management Inc. bought a new position in Supernus Pharmaceuticals during the 2nd quarter valued at approximately $17,220,000. 94.70% of the stock is owned by institutional investors.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.